Cytokine profiles at admission can be related to outcome in AIDS patients with cryptococcal meningitis.

Delio José Mora, Laila Rigolin Fortunato, Leonardo Eurípedes Andrade-Silva, Kennio Ferreira-Paim, Ivonete Helena Rocha, Rakel Rocha Vasconcelos, David Nascimento Silva-Teixeira, Gabriel Antonio Nogueira Nascentes, Mario León Silva-Vergara
Author Information
  1. Delio José Mora: Infectious Diseases Unit, Internal Medicine Department, Triângulo Mineiro Federal University, Uberaba, Minas Gerais, Brazil.
  2. Laila Rigolin Fortunato: Infectious Diseases Unit, Internal Medicine Department, Triângulo Mineiro Federal University, Uberaba, Minas Gerais, Brazil.
  3. Leonardo Eurípedes Andrade-Silva: Infectious Diseases Unit, Internal Medicine Department, Triângulo Mineiro Federal University, Uberaba, Minas Gerais, Brazil.
  4. Kennio Ferreira-Paim: Infectious Diseases Unit, Internal Medicine Department, Triângulo Mineiro Federal University, Uberaba, Minas Gerais, Brazil.
  5. Ivonete Helena Rocha: Infectious Diseases Unit, Internal Medicine Department, Triângulo Mineiro Federal University, Uberaba, Minas Gerais, Brazil.
  6. Rakel Rocha Vasconcelos: Infectious Diseases Unit, Internal Medicine Department, Triângulo Mineiro Federal University, Uberaba, Minas Gerais, Brazil.
  7. David Nascimento Silva-Teixeira: Infectious Diseases Unit, Internal Medicine Department, Triângulo Mineiro Federal University, Uberaba, Minas Gerais, Brazil.
  8. Gabriel Antonio Nogueira Nascentes: Federal Institute of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil.
  9. Mario León Silva-Vergara: Infectious Diseases Unit, Internal Medicine Department, Triângulo Mineiro Federal University, Uberaba, Minas Gerais, Brazil.

Abstract

Cryptococcal meningitis (CM) remains as common life-threatening AIDS-defining illness mainly in resource-limited settings. Previous reports suggested that baseline cytokine profiles can be associated to fungal burden and clinical outcome. This study aimed to evaluate the baseline cytokine profiles in AIDS patients with CM and its relation with the outcome at weeks 2 and 10. Thirty AIDS patients with CM diagnosed by cerebrospinal fluid (CSF) Cryptococcus neoformans positive culture, India ink stain and cryptococcal antigen test were prospectively evaluated. As controls, 56 HIV-infected patients without CM and 48 non-HIV individuals were included. Baseline CSF and sera levels of IL-2, IL-4, IL-8, IL-10, IL-12p40, IL-17A, INF-γ and TNF-α were measured by ELISA. Of 30 CM patients, 24 (80%) were male, median age of 38.1. The baseline CSF high fungal burden and positive blood culture were associated with a positive CSF culture at week 2 (p = 0.043 and 0.029). Most CSF and sera cytokines presented higher levels in CM patients than control subjects (p < 0.05). CSF levels of IL-8, IL-12p40, IL-17A, TNF-α, INF-γ and sera TNF-α were significantly higher among survivors at weeks 2 and 10 (p < 0.05). Patients with increased intracranial pression exhibited CSF IL-10 high levels and poor outcome at week 10 (p = 0.032). Otherwise, baseline CSF log10 IFN-γ and IL-17A were negatively correlated with fungal burden (r = -0.47 and -0.50; p = 0.0175 and 0.0094, respectively). The mortality rate was 33% (10/30) at week 2 and 57% (17/30) at week 10. The severity of CM and the advanced immunodeficiency at admission were related to a poor outcome in these patients. Otherwise, the predominant Th1 cytokines profile among survivors confirms its pivotal role to infection control and would be a prognostic marker in cryptococcal meningitis.

References

  1. Transpl Immunol. 2006 Aug;16(2):69-72 [PMID: 16860707]
  2. Jpn J Infect Dis. 2004 Aug;57(4):137-45 [PMID: 15329444]
  3. PLoS One. 2013;8(5):e63632 [PMID: 23741297]
  4. Crit Rev Immunol. 2007;27(6):547-57 [PMID: 18197800]
  5. Lancet. 2004 May 29;363(9423):1764-7 [PMID: 15172774]
  6. Rev Inst Med Trop Sao Paulo. 2008 Mar-Apr;50(2):75-8 [PMID: 18488084]
  7. PLoS Pathog. 2013;9(7):e1003472 [PMID: 23853593]
  8. J Neurol Neurosurg Psychiatry. 1970 Aug;33(4):415-25 [PMID: 5535907]
  9. Clin Infect Dis. 2009 Sep 1;49(5):702-9 [PMID: 19613840]
  10. Braz J Infect Dis. 2013 May-Jun;17(3):353-62 [PMID: 23665012]
  11. J Immunol. 2005 Feb 1;174(3):1746-50 [PMID: 15661940]
  12. PLoS One. 2011;6(2):e17204 [PMID: 21359196]
  13. PLoS Med. 2007 Feb;4(2):e21 [PMID: 17284154]
  14. Immunol Rev. 2008 Dec;226:205-18 [PMID: 19161426]
  15. J Infect Dis. 2001 Jan 15;183(2):294-302 [PMID: 11110651]
  16. Antimicrob Agents Chemother. 1994 Mar;38(3):460-4 [PMID: 7911289]
  17. Epidemiol Infect. 2010 Jul;138(7):1036-43 [PMID: 19796452]
  18. J Virol. 2009 Apr;83(8):3719-33 [PMID: 19176632]
  19. Antivir Chem Chemother. 2001 May;12(3):133-50 [PMID: 12959322]
  20. Roum Arch Microbiol Immunol. 2010 Jan-Mar;69(1):24-34 [PMID: 21053781]
  21. Curr Opin HIV AIDS. 2010 Jan;5(1):18-26 [PMID: 20046144]
  22. Clin Infect Dis. 2014 Mar;58(5):736-45 [PMID: 24319084]
  23. AIDS. 2009 Feb 20;23(4):525-30 [PMID: 19182676]
  24. J Infect Dis. 1998 Jan;177(1):260-3 [PMID: 9419203]
  25. Clin Infect Dis. 2008 Jun 1;46(11):1694-701 [PMID: 18433339]
  26. Int J STD AIDS. 2011 Nov;22(11):665-70 [PMID: 22096053]
  27. J Infect Dis. 2014 Jan 1;209(1):74-82 [PMID: 23945372]
  28. Infect Immun. 2007 Jun;75(6):3055-61 [PMID: 17403873]
  29. J Infect Dis. 2001 Jan 1;183(1):51-8 [PMID: 11087201]
  30. J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):287-94 [PMID: 10836750]
  31. J Immunol. 2007 May 1;178(9):5753-61 [PMID: 17442959]
  32. Emerg Infect Dis. 2003 Feb;9(2):189-95 [PMID: 12603989]
  33. Infect Immun. 2000 Feb;68(2):456-62 [PMID: 10639404]
  34. J Infect Dis. 1997 Dec;176(6):1633-6 [PMID: 9395381]
  35. Clin Exp Immunol. 1996 May;104(2):208-14 [PMID: 8625510]
  36. AIDS Res Ther. 2010 Aug 03;7:29 [PMID: 20682061]
  37. J Infect Dis. 2004 Jun 15;189(12):2185-91 [PMID: 15181565]
  38. PLoS Med. 2010;7(12):e1000384 [PMID: 21253011]
  39. Am J Pathol. 2009 Dec;175(6):2489-500 [PMID: 19893050]
  40. J Clin Microbiol. 1982 Mar;15(3):535-7 [PMID: 7042750]
  41. Am J Pathol. 2009 Feb;174(2):486-96 [PMID: 19147811]
  42. Clin Microbiol Infect. 2005 Apr;11(4):296-300 [PMID: 15760426]
  43. Int J STD AIDS. 2000 Jan;11(1):49-51 [PMID: 10667901]
  44. J Antimicrob Chemother. 2000 Sep;46(3):437-42 [PMID: 10980171]
  45. Curr Med Chem. 2004 Jan;11(2):253-66 [PMID: 14754421]
  46. Clin Infect Dis. 2004 Nov 1;39(9):e83-7 [PMID: 15494899]
  47. J Infect. 2011 Dec;63(6):484-6 [PMID: 21930156]
  48. Clin Infect Dis. 2010 Feb 1;50(3):338-44 [PMID: 20038244]
  49. Med Mycol. 2005 Feb;43(1):27-38 [PMID: 15712606]
  50. Mycopathologia. 2012 Jun;173(5-6):321-7 [PMID: 22130645]
  51. AIDS. 2010 Jan 28;24(3):405-10 [PMID: 19952714]
  52. J Immunol. 2005 Jan 15;174(2):1027-36 [PMID: 15634927]
  53. Antimicrob Agents Chemother. 2001 Mar;45(3):686-9 [PMID: 11181343]
  54. J Immunol. 2005 Jun 15;174(12):7920-8 [PMID: 15944298]
  55. ISRN AIDS. 2013 Feb 25;2013:471363 [PMID: 24052889]
  56. AIDS. 2014 Mar 13;28(5):657-66 [PMID: 24451162]
  57. Infect Immun. 2009 Aug;77(8):3450-7 [PMID: 19487474]
  58. J Infect Dis. 2013 Jun 15;207(12):1817-28 [PMID: 23493728]
  59. AIDS. 2012 Jun 1;26(9):1105-13 [PMID: 22421244]
  60. PLoS One. 2013;8(2):e56269 [PMID: 23457543]
  61. BMC Immunol. 2012;13:65 [PMID: 23216912]
  62. PLoS One. 2013;8(3):e60431 [PMID: 23555970]
  63. J Infect. 2008 Sep;57(3):260-5 [PMID: 18707764]
  64. Epilepsia. 2013 Sep;54(9):e142-5 [PMID: 23944193]
  65. Infect Immun. 2007 Mar;75(3):1453-62 [PMID: 17210668]
  66. Cytokine. 2014 Sep;69(1):62-7 [PMID: 25022963]
  67. Curr Med Chem. 2003 Aug;10(16):1581-91 [PMID: 12871129]
  68. Clin Infect Dis. 2007 Jul 1;45(1):76-80 [PMID: 17554704]

MeSH Term

AIDS-Related Opportunistic Infections
Adult
Biomarkers
Female
Humans
Interferon-gamma
Interleukins
Male
Meningitis, Cryptococcal
Middle Aged
Prognosis
Tumor Necrosis Factor-alpha

Chemicals

Biomarkers
Interleukins
Tumor Necrosis Factor-alpha
Interferon-gamma

Word Cloud

Created with Highcharts 10.0.0CSFCMpatients0outcomepbaseline210levelsweek=meningitisprofilesfungalburdenAIDSpositiveculturecryptococcalseraIL-17ATNF-αcytokinecanassociatedweeksIL-8IL-10IL-12p40INF-γhighcytokineshighercontrol<05amongsurvivorspoorOtherwise-0admissionrelatedCryptococcalremainscommonlife-threateningAIDS-definingillnessmainlyresource-limitedsettingsPreviousreportssuggestedclinicalstudyaimedevaluaterelationThirtydiagnosedcerebrospinalfluidCryptococcusneoformansIndiainkstainantigentestprospectivelyevaluatedcontrols56HIV-infectedwithout48non-HIVindividualsincludedBaselineIL-2IL-4measuredELISA302480%malemedianage381blood043029presentedsubjectssignificantlyPatientsincreasedintracranialpressionexhibited032log10IFN-γnegativelycorrelatedr475001750094respectivelymortalityrate33%10/3057%17/30severityadvancedimmunodeficiencypredominantTh1profileconfirmspivotalroleinfectionprognosticmarkerCytokine

Similar Articles

Cited By